Abstract Benign breast disease (BBD) confers elevated risk for breast cancer, yet current tools lack precision in identifying lesions likely to progress. Immune mechanisms may influence progression, but the spatial and molecular features of immune responses in BBD versus invasive cancer remain poorly characterized. We applied Digital Spatial Proteomics (DSP) to evaluate immune-related protein expression across 1,540 regions of interest (ROIs) from breast tumors (n=58, Carolina Breast Cancer Study CBCS), a UNC BBD cohort (n=20), and a Mayo BBD cohort (n=177). Using Consensus Clustering in CBCS and UNC BBD, we identified two stable immune phenotypes: “High Immune,” enriched in tumors and high-risk benign lesions, and “Quiet Immune,” predominant in low-risk BBD. ROIs were classified by immune marker expression, and patients were labeled as “High” if ≥50% of their ROIs were High Immune. In CBCS, High Immune profiles were associated with ER-negative status (OR=2.92 0.99-8.65 participant-level; OR=3.28 1.34-8.04 ROI-level). In BBD, High Immune profiles trended toward higher odds of high-risk lesions (OR=1.00 0.15-6.70 participant-level; OR=1.68 0.57-4.97 ROI-level), though this pattern was not replicated in the Mayo cohort. BBD samples exhibited substantial spatial heterogeneity in immune expression (40% within-patient ROI agreement vs. 74% in tumors), potentially limiting biomarker reliability. Nonetheless, four immune proteins (CD44, CD80, CD14, CD66b) were significantly associated with future cancer development in the Mayo cohort, though these findings require validation due to within-person variability. Our findings highlight the challenges posed by spatial heterogeneity in assessing immune biomarkers in BBD and suggest that immune activation may emerge later in disease progression. These results raise important questions about the timing and consistency of immune responses in the natural history of breast cancer. Citation Format: A. Zhang, A. Cozzo, L. Olsson, E. Kirk, X. Gao, S. Nyante, B. Calhoun, R. Vierkant, M. Sherman, M. Troester. Immune Heterogeneity in Breast Cancer Natural History: Benign Breast Disease to Breast Cancer abstract. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-05-23.
Zhang et al. (Tue,) studied this question.